What is the clinical evidence from this study?

Study design: Case Report. Population: Anti-Ku myositis with progressive inflammatory myocarditis (n=1). Intervention: Anti-Ku myositis. Primary outcome: Cardiac function and survival.

What does this research mean for the field?

Anti-Ku myositis can present with aggressive, treatment-refractory inflammatory myocarditis that precedes overt muscle symptoms, necessitating early autoimmune testing in cases of unexplained cardiomyopathy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To describe a fatal presentation of anti-Ku overlap myositis masquerading as isolated cardiac disease and identify clinical pitfalls in diagnosis and management.

September 2, 2026European Heart Journal - Case ReportsOpen Access

Anti-Ku Myositis Presenting with Progressive Inflammatory myocarditis: Diagnostic Pitfalls in a Fatal Case: Case Report

View Full Paper

Ask AI

Bookmark

Key result

Anti-Ku myositis linked to fatal inflammatory myocarditis with LVEF declining to 12% despite aggressive immunosuppression.

Why the study?

Anti-Ku antibodies often signal multisystem involvement in overlap myositis, but overt heart failure is seldom reported.

Population

A 60-year-old man presenting with progressive exertional dyspnoea and chest tightness

Design

Case report

Authors

AEAhmed ELBekieyPrincess Alexandra Hospital NHS Trust MZMohamed Wahib ZhlawiPrincess Alexandra Hospital NHS Trust JTJie TongPrincess Alexandra Hospital NHS Trust

Discussion

Member takes

Overview

Highlights potential fatality in anti-Ku myocarditis despite immunosuppression; leaves open role of early antibody screening.

Key Points

To describe a fatal presentation of anti-Ku overlap myositis masquerading as isolated cardiac disease and identify clinical pitfalls in diagnosis and management.
Clinical, diagnostic, and therapeutic evaluation of a 60-year-old male presenting with progressive heart failure and subsequent proximal myopathy.
Diagnostic procedures included serial echocardiography, coronary angiography, cardiac MRI, deltoid muscle biopsy, and myositis-specific antibody immunoblotting.
Left-ventricular ejection fraction progressively declined from an initial 49% to 12%, complicated by high-grade atrioventricular block requiring dual-chamber pacing.
Immunoblot confirmed high-titre anti-Ku antibodies and deltoid biopsy showed inflammatory myopathy, alongside serum creatine kinase of 2,680 IU/L and troponin I of 928 ng/L.
Despite combination immunosuppression with corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin, cardiac failure proved refractory, resulting in death at eight months.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A 60-year-old man with anti-Ku myositis presenting with progressive inflammatory myocarditis and heart failure, followed for 8 months until death.

Exposure

High-dose corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin

Outcome

Clinical course and survival

Anti-Ku myositis can present with aggressive cardiac involvement and may be refractory to conventional immunosuppression once advanced cardiomyopathy is established.

Cite This Study

ELBekiey et al. (2026) conducted a case report in Anti-Ku myositis with progressive inflammatory myocarditis (n=1). Anti-Ku myositis was evaluated on Cardiac function and survival. Anti-Ku myositis in a 60-year-old man led to fatal progressive inflammatory myocarditis, with left ventricular ejection fraction declining from 49% to 12% despite aggressive immunosuppression.

synapsesocial.com/papers/6a97e2eac562ede874ec7441 https://doi.org/10.1093/ehjcr/ytag625

View Full Paper

Ask AI

Bookmark

September 2, 2026European Heart Journal - Case ReportsOpen Access

Anti-Ku Myositis Presenting with Progressive Inflammatory myocarditis: Diagnostic Pitfalls in a Fatal Case: Case Report

View Full Paper

Ask AI

Bookmark

Key result

Anti-Ku myositis linked to fatal inflammatory myocarditis with LVEF declining to 12% despite aggressive immunosuppression.

Why the study?

Anti-Ku antibodies often signal multisystem involvement in overlap myositis, but overt heart failure is seldom reported.

Population

A 60-year-old man presenting with progressive exertional dyspnoea and chest tightness

Design

Case report

Authors

AEAhmed ELBekieyPrincess Alexandra Hospital NHS Trust MZMohamed Wahib ZhlawiPrincess Alexandra Hospital NHS Trust JTJie TongPrincess Alexandra Hospital NHS Trust

Discussion

Member takes

Overview

Highlights potential fatality in anti-Ku myocarditis despite immunosuppression; leaves open role of early antibody screening.

Key Points

To describe a fatal presentation of anti-Ku overlap myositis masquerading as isolated cardiac disease and identify clinical pitfalls in diagnosis and management.
Clinical, diagnostic, and therapeutic evaluation of a 60-year-old male presenting with progressive heart failure and subsequent proximal myopathy.
Diagnostic procedures included serial echocardiography, coronary angiography, cardiac MRI, deltoid muscle biopsy, and myositis-specific antibody immunoblotting.
Left-ventricular ejection fraction progressively declined from an initial 49% to 12%, complicated by high-grade atrioventricular block requiring dual-chamber pacing.
Immunoblot confirmed high-titre anti-Ku antibodies and deltoid biopsy showed inflammatory myopathy, alongside serum creatine kinase of 2,680 IU/L and troponin I of 928 ng/L.
Despite combination immunosuppression with corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin, cardiac failure proved refractory, resulting in death at eight months.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A 60-year-old man with anti-Ku myositis presenting with progressive inflammatory myocarditis and heart failure, followed for 8 months until death.

Exposure

High-dose corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin

Outcome

Clinical course and survival

Anti-Ku myositis can present with aggressive cardiac involvement and may be refractory to conventional immunosuppression once advanced cardiomyopathy is established.

Cite This Study

synapsesocial.com/papers/6a97e2eac562ede874ec7441 https://doi.org/10.1093/ehjcr/ytag625

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark